Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Inovio Pharmaceuticals, Inc. (INO)

Add INO Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Tonyeight, KarinCA, kablahm, biovalidator, KingDMC
Search This Board:
Last Post: 10/24/2014 11:05:09 AM - Followers: 403 - Board type: Free - Posts Today: 1

Logo: Inovio

ebruary 12, 2014 Inovio CEO Dr. Joseph Kim rings bell to open trading on NYSE-

Float: 97.65 M

Shares Outstanding: 127.26 M

Inovio Biomedical Corporation engages in the design, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The company?s SynCon technology enables the design of DNA-based vaccines capable of providing cross-protection against evolving, unmatched strains of pathogens, such as influenza. Inovio?s proprietary electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. The company also has access to formulation and manufacturing expertise, and technology through its controlling ownership in VGX International. Inovio?s clinical programs include trials for HPV/cervical cancer (therapeutic) and HIV vaccines; and an IND has been filed for an avian influenza vaccine. Its partners and collaborators include Roche,Merck, Tripep, University of Southampton, University of Pennsylvania, HIV Vaccines Trial Network, and National Microbiology Laboratory of the Public Health Agency of Canada. The company was formerly known as Genetronics Biomedical Corp. and changed its name to Inovio Biomedical Corporation in March 2005. The company was founded in 1983 and is based in San Diego, California.

Currently Inovio has 12 clinical studies ( HIV, Influenza, Malaria, Hepatitis B, Hepatitis C, Breast and Lung cancer, Prostate Cancer, Head and Neck cancer, Cervical Cancer, Cervical dysplasia caused by HPV) ongoing from preclinical to phase 2.
Sep 10, 2013
Roche and Inovio Pharmaceuticals partner on Inovio's prostate cancer and hepatitis B immunotherapy products. Roche will make an upfront payment of USD $10 million to Inovio. Roche will also provide preclinical R&D support and payments for near-term regulatory milestones as well as payments upon reaching certain development and commercial milestones potentially up to USD $412.5 million. Additional development milestone payments could also be made to Inovio if Roche pursues other indications with INO-5150 or INO-1800.  In addition, Inovio is entitled to receive up to double-digit tiered royalties on product sales.

VGX-3100-Phase 2 Clinical Trial initiated for the treatment Cervical dysplasia (cervical intraepithelial neoplasia or CIN) caused by HPV
Top line data release Mid 2014
May 13, 2014:  Inovio Pharmaceuticals Acquires Early Stage DNA Therapies to Treat Alzheimer's and Multiple Sclerosis

May 23, 2014: Inovio Pharmaceuticals Announces 1 For 4 Reverse Split
1-for-4 reverse stock split shall become effective at 5 P.M., Thursday, June 5, 2014, and trading of the Company's common stock on a post-reverse split basis shall commence on Friday, June 6, 2014.

Inovio’s goal is to revolutionize vaccines. With best-in-class immune responses from multiple vaccines in different disease areas, our synthetic vaccine technology is making big strides toward this important goal.



#11886  Sticky Note INOVIO RESPONDS - FRESH OFF THE PRESS - CCruzNY 06/11/14 09:10:07 AM
#4698  Sticky Note Please stay on topic. The only topic to IH Admin [Dan] 08/02/13 01:15:33 PM
#12640   Everywhereman- first it's good to have you posting! future1 10/24/14 11:05:09 AM
#12639   Another patient. Vaccine needed ASAP! billymayshear 10/23/14 08:51:51 PM
#12638   Does the current ebola coverage and inflows from Everywhereman 10/23/14 06:49:48 PM
#12637   Will load up again below 10, its going harry crumb 10/22/14 08:51:07 PM
#12636   Lets hope it dosen't curb the volatility on celtic 10/22/14 10:24:27 AM
#12635   Remember when one of the "reasons" for the ImaPseudonym 10/22/14 09:58:43 AM
#12634 celtic 10/22/14 09:39:31 AM
#12633   Another article on the Inovio/Darpa/UPenn/Medimmune collaboration. johan31 10/22/14 08:59:44 AM
#12632   Great news about funding for DNA based mAB KMBJN 10/21/14 03:16:22 PM
#12631   Dara to restart its Ebola program weeeeeee akamaii 10/21/14 01:11:14 PM
#12630   From what I understand there was a significant future1 10/21/14 01:03:24 PM
#12629   Not sure why this is down? Doesn't make MountainMom 10/21/14 12:51:04 PM
#12628   Modified antibodies - aka mAbs - gangbusters!!!! nanopatent 10/21/14 09:41:35 AM
#12627   MRatt.....thanks for the post. I just caught this johan31 10/21/14 01:22:35 AM
#12626   NEWS! DARPA AWARD MRatt 10/21/14 12:59:34 AM
#12625   Dr. Kim on FOX News today biovalidator 10/20/14 10:13:07 PM
#12624   Great video by a great CEO speaking about nanopatent 10/20/14 01:06:57 PM
#12623   Agreed! Been long for a long time now. KingDMC 10/20/14 10:35:50 AM
#12622   FROM BLOOMBERG NEWS: MRatt 10/20/14 10:28:26 AM
#12621   Inovio is a great stock with great products nanopatent 10/20/14 09:59:25 AM
#12620   Let them short they will pay! KingDMC 10/20/14 09:56:12 AM
#12619   INO had the highest ranking on short 2th Dr 10/19/14 09:59:58 PM
#12618   Why INO has a $29 Price Target... MountainMom 10/19/14 03:03:07 PM
#12617   Inovio All systems go! MRatt 10/19/14 07:04:17 AM
#12616   News Coverage Link OCT 17. 2014 Tonyxhalo 10/18/14 10:00:48 AM
#12615   He's been spot on too so far. According Perkin78 10/17/14 10:27:45 AM
#12614   Thanks Clay......I appreciate the time & effort. johan31 10/17/14 09:04:44 AM
#12613   * * $INO Video Chart 10-16-14 * * ClayTrader 10/16/14 04:53:02 PM
#12612   This INO is rapidly overtaking Merck! nanopatent 10/16/14 01:26:24 PM
#12611   Interesting article on watch period for symptoms of billymayshear 10/15/14 10:43:07 PM
#12610   EXCELLENT post johan.....appreciate you sharing your thoughts on twiz0019 10/15/14 04:28:53 PM
#12609   A nice close today. Great consolidation above 11.00 johan31 10/15/14 04:16:56 PM
#12608   Nice thing is that INO is not a billymayshear 10/15/14 03:50:09 PM
#12607   Many thanks for taking the time to respond MountainMom 10/15/14 03:23:53 PM
#12606 response to your question I'll give you johan31 10/15/14 03:12:11 PM
#12605   For johan31 would appreciate your thoughts: MountainMom 10/15/14 02:16:22 PM
#12604   Another Abstract from Gene Therapy advanced online publication... johan31 10/15/14 02:00:33 PM
#12603   New Abstract at PubMed from Weiner et al......... johan31 10/15/14 01:47:03 PM
#12602   It seems like if Inovio took the initiative Autumnforest 10/15/14 01:34:12 PM
#12601   Agree. Without a vaccine no healthcare workers will billymayshear 10/15/14 01:23:46 PM
#12600   Breaking News...President convenes crisis meeting on Ebola with Cabinet MountainMom 10/15/14 01:07:51 PM
#12599   Sorry didn't mean to re-post that I was MountainMom 10/15/14 01:03:15 PM
#12598   Please read johan31's post from below. It pretty MountainMom 10/15/14 12:16:29 PM
#12597   and i asked this very question on the uncleguts99 10/15/14 12:05:55 PM
#12596   I'm smart - the rest who are not nanopatent 10/15/14 11:37:18 AM
#12595   why are you the only person allowed to uncleguts99 10/15/14 06:53:56 AM
#12594   Johan Thanks for your post INO has so much celtic 10/14/14 08:58:28 PM
#12593   The comparison of kite to Inovio is apples johan31 10/14/14 06:59:06 PM
#12592   Who is/are the moderator/s around here? nanopatent 10/14/14 05:14:00 PM
#12591   Dynarod- while the report was good the numbers future1 10/14/14 04:36:28 PM